OCX Insider Trading

Insider Ownership Percentage: 1.58%
Insider Buying (Last 12 Months): $13,851,500.79
Insider Selling (Last 12 Months): $0.00

OncoCyte Insider Trading History Chart

This chart shows the insider buying and selling history at OncoCyte by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$5M$0$5MTotal Insider BuyingTotal Insider Selling

OncoCyte Share Price & Price History

Current Price: $2.85
Price Change: Price Decrease of -0.15 (-5.00%)
As of 04/2/2025 03:50 PM ET

This chart shows the closing price history over time for OCX up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MayJunJulAugSepOctNovDecJanFebMar$3.00Closing price on 04/01/25:

SEC Filings (Institutional Ownership Changes) for OncoCyte (NASDAQ:OCX)

55.35% of OncoCyte stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at OCX by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$4.53Mbought$916ksoldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$40M-$20M$0$20M$40MTotal InflowsTotal Outflows
OncoCyte logo
OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test. It also provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests. The company has a collaboration agreement with Bio-Rad Laboratories, Inc. (Bio-Rad) to collaborate in the development and the commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad's ddPCR instruments and reagents. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.
Read More on OncoCyte

Today's Range

Now: $2.85
Low: $2.85
High: $3.03

50 Day Range

MA: $2.83
Low: $1.96
High: $4.17

52 Week Range

Now: $2.85
Low: $1.92
High: $4.75

Volume

25,584 shs

Average Volume

65,296 shs

Market Capitalization

$81.51 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.79

Who are the company insiders with the largest holdings of OncoCyte?

OncoCyte's top insider investors include:
  1. Broadwood Partners, LP (Major Shareholder)
  2. Patrick W Smith (Major Shareholder)
  3. Pura Vida Investments, Llc (Major Shareholder)
  4. Andrea S James (CFO)
  5. Andrew Arno (Director)
  6. Alfred D Kingsley (Director)
  7. Josh Riggs (CEO)
Learn More about top insider investors at OncoCyte.